Get the Daily Brief
Latest Biotech News
Soleno’s rare disease drug Vykat XR beats sales expectations
Soleno Therapeutics reported early sales figures for Vykat XR, the first approved treatment for hyperphagia in Prader-Willi syndrome. The medicine’s net revenue for Q2 2025 is forecast between $31...
GREmLN AI model maps gene regulatory networks to decode cell behavior
Scientists from Columbia University and the Chan Zuckerberg Initiative developed GREmLN, a graph-based artificial intelligence model that better captures complex gene regulatory interactions than...
Juniper Genomics raises C$4.6M to expand IVF genomics testing
Juniper Genomics secured $3.5 million USD (approximately C$4.6 million) in seed funding to commercialize its genomics testing platform tailored for in vitro fertilization (IVF). The startup aims...
Biomanufacturing faces talent shortage risk by 2028, experts warn
Industry experts highlight a looming 'talent singularity' in biomanufacturing by 2028, driven by a shortage of skilled workers aligned with evolving technological demands. Jason Beckwith of...
Merck’s $10B Bet on Verona Expands COPD Pipeline
Merck & Co. has completed a $10 billion acquisition of Verona Pharma, adding the fast-growing COPD drug Ohtuvayre to its cardio-pulmonary portfolio. This inhaled dual inhibitor of PDE3 and PDE4...
FDA Unveils Drug Rejection Letters in Transparency Shift
The FDA has published over 200 complete response letters (CRLs), revealing reasons for drug application rejections between 2020 and 2024. These letters, for products later approved, provide...
AbbVie Pays $700M for IGI’s Trispecific Multiple Myeloma Antibody
AbbVie has secured global rights to IGI Therapeutics’ early-stage trispecific antibody, ISB-2001, targeting BCMA, CD38, and CD3 for multiple myeloma treatment. The $700 million upfront deal could...
Capricor’s Duchenne Muscular Dystrophy Cell Therapy Faces FDA Setback
Capricor Therapeutics has received a complete response letter (CRL) from the FDA rejecting its Biologics License Application (BLA) for deramiocel, an off-the-shelf cell therapy aimed at treating...
AI Models Revolutionize Cell Biology and Drug Discovery
Researchers from Columbia University and the Chan Zuckerberg Initiative have developed GREmLN, an AI-based virtual cell model that captures complex gene regulatory networks. Utilizing graph-based...
Soleno’s Rare Disease Drug Surges Past Expectations in Q2
Soleno Therapeutics’ first-quarter sales of Vykat XR, a treatment for the insatiable hunger in Prader-Willi syndrome, exceeded market forecasts with $31–33 million in net revenues. The launch...
Nuclidium and Actithera Lead New Wave in Radiopharmaceuticals Funding
The European radiopharma sector gains momentum as Nuclidium AG closed a CHF 79 million ($99 million) Series B funding round, advancing clinical development of copper isotope-based diagnostics and...
Advances in Antibody and Protein Engineering Platforms
Emerging technologies are shaping antibody and protein engineering: Cellecta introduced DriverMap scAIR kits enabling detailed T and B cell receptor sequencing at single-cell resolution without...
Jazz Pharmaceuticals Names Renée Galá as New CEO
Jazz Pharmaceuticals announced that its current President and Chief Operating Officer, Renée Galá, will succeed CEO and co-founder Bruce Cozadd, effective August 11. This leadership change follows...
Merck Acquires Verona Pharma in $10 Billion Deal for COPD Pipeline
Merck & Co. announced the acquisition of Verona Pharma for $10 billion, aiming to enhance its portfolio in cardio-pulmonary disease treatments with the inclusion of Verona's COPD drug, Ohtuvayre....
FDA Publishes Rejection Letters to Improve Transparency in Drug Approvals
In an unprecedented move, the FDA has released an initial batch of over 200 complete response letters (CRLs) issued from 2020 to 2024, offering insight into deficiencies cited in drug approval...
FDA Rejects Capricor’s Cell Therapy for Duchenne Muscular Dystrophy
The FDA issued a complete response letter (CRL) to Capricor Therapeutics, rejecting their biologics license application for deramiocel, a cell therapy aimed at treating cardiomyopathy in Duchenne...
AbbVie Inks $700 Million Deal for Trispecific Antibody in Multiple Myeloma
AbbVie has acquired global rights to a trispecific antibody, ISB-2001, from IGI Therapeutics for $700 million upfront, with potential milestone and royalty payments reaching nearly $2 billion. The...
Launch of Center for Pediatric CRISPR Therapies Funded by CZI and IGI
The Chan Zuckerberg Initiative and the Innovative Genomics Institute have jointly funded a new Center for Pediatric CRISPR Cures with a $20 million grant. The center aims to advance personalized...
New AI Models Advance Prediction of Cell and Protein Dynamics
Innovative AI platforms are reshaping biological modeling, improving insights into cell behavior and protein dynamics essential for drug discovery. The GREmLN model developed by Columbia...
Soleno Therapeutics Reports Strong Early Sales for Prader-Willi Syndrome Drug
Soleno Therapeutics’ Vykat XR, the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome, has exceeded expectations in its initial full-quarter sales, with net revenues projected...